title: Serologic immunity to diphtheria and tetanus in the United States.
abstract: BACKGROUND
  Serologic data on diseases that are preventable by vaccine are useful to evaluate the success of immunization programs and to identify susceptible subgroups.
  
  
  OBJECTIVE
  To provide national estimates of immunity to diphtheria and tetanus by measurement of serum antibody levels.
  
  
  METHODS
  Examination of data from the Third National Health and Nutrition Examination Survey, a representative cross-sectional sample of the U.S. population.
  
  
  METHODS
  89 randomly selected locations throughout the United States.
  
  
  METHODS
  18 045 persons 6 years of age or older who were examined from 1988 to 1994.
  
  
  METHODS
  Serum samples obtained at a single time point were tested for diphtheria and tetanus antitoxin.
  
  
  RESULTS
  Overall, 60.5% of Americans 6 years of age or older had fully protective levels of diphtheria antibody (> or =0.10 IU/mL) and 72.3% had protective levels of tetanus antibody (> 0.15 IU/mL). Ninety-one percent of Americans 6 to 11 years of age had protective levels of both diphtheria and tetanus antibody; this proportion decreased to approximately 30% among persons 70 years of age (29.5% for diphtheria and 31.0% for tetanus). Adult Mexican-Americans were slightly less likely to have protective levels of antibody to both toxins. Only 47% of persons 20 years of age or older had levels that were protective against both diseases, and only 63% of adults who were protected against tetanus were also protected against diphtheria.
  
  
  CONCLUSIONS
  A substantial proportion of adults in the United States do not have antibody levels that are protective against diphtheria and tetanus. In addition, although the recommended vaccine is a combination of tetanus and diphtheria, only 63% of adults with protective antibody to tetanus also had protective antibody to diphtheria.
authors: Division of Health Examination Statistics, National Center for Health Statistics, Hyattsville, MD 20782, USA. gmm2@cdc.gov
authors: Geraldine M
authors: GM
authors: McQuillan
authors: Deanna
authors: D
authors: Kruszon-Moran
authors: Adamadia
authors: A
authors: Deforest
authors: Susan Y
authors: SY
authors: Chu
authors: Melinda
authors: M
authors: Wharton
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D002648:Child; D003430:Cross-Sectional Studies; D004165:Diphtheria / Q000276:immunology* / Q000517:prevention & control; D022422:Diphtheria-Tetanus Vaccine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012959:Socioeconomic Factors; D013742:Tetanus / Q000276:immunology* / Q000517:prevention & control; D014481:United States / Q000453:epidemiology
chemical_list: D000907:Antibodies, Bacterial; D022422:Diphtheria-Tetanus Vaccine